Evidence map›Paper›PMID 35265774›Full record

ArticleAmerican journal of ophthalmology case reports2022

Immunotherapy-induced retinopathy mimicking cancer associated retinopathy.

Hashem Ghoraba, Christopher Or, Irmak Karaca, Kapil Mishra, Amir Akhavanrezayat, Sungwho Park, Ngoc Than, Loh-Shan Leung, Steven Sanislo, Quan Dong Nguyen

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hashem GhorabaByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Christopher OrByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Irmak KaracaByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Kapil MishraByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Amir AkhavanrezayatByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Sungwho ParkByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Ngoc ThanByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Loh-Shan LeungByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Steven SanisloByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Quan Dong NguyenByers Eye Institute, Stanford University, Palo Alto, CA, USA.
Smith-Kettlewell Eye Research Institute · US

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026
$8.0M
NEI NIH HHS P30 EY026877
6 · The paper itself

Abstract

Purpose: To report a patient who developed a cancer associated retinopathy (CAR) like syndrome in the setting of pembrolizumab and lenvatinib combination therapy for metastatic endometrial carcinoma. Symptoms resolved with normalization of objective functional tests following cessation of medications. Observations: A 52-year-old female with history of endometrial carcinoma, managed with pembrolizumab infusions and daily oral lenvatinib treatment for 18 months, presented to a tertiary eye center with complaints of nyctalopia, photosensitivity and photopsia. Further investigations revealed a reduction in b-wave amplitude on full field ERG (ffERG), a mild color vision deficit, and positive antiretinal antibodies against carbonic anhydrase II, enolase and arrestin. A preliminary diagnosis of CAR was made. One month following diagnosis, the patient discontinued both lenvatinib and pembrolizumab and subsequently reported significant improvement in her eye symptoms and vision. Repeat ffERG had normalized with a robust b-wave, with an improvement noted on repeat color vision testing. A presumed diagnosis of immunotherapy-induced retinopathy was made, with clinical findings mimicking CAR. Conclusions and importance: Pembrolizumab and lenvatinib treatment may be associated with a reversible retinopathy, with presentation very similar to CAR.

Indexed as

Cancer associated retinopathyCheckpoint inhibitorsImmunotherapyLenvatinibOcular adverse eventsPembrolizumab

Identifiers

PMID35265774
PMCPMC8899240
OpenAlexW4214640718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.